Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Outpatients With MDS and AML
NCT06599762Phase 2Recruiting
- Sponsor
- University of Manitoba
- Start
- Sep 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tranexamic acid in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by University of Manitoba. Started Sep 2025; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT06599762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599762.